Cast no shadow: assessing the disease-modifying effects of elexacaftor/tezacaftor/ivacaftor
- PMID: 38061794
- DOI: 10.1183/13993003.02026-2023
Cast no shadow: assessing the disease-modifying effects of elexacaftor/tezacaftor/ivacaftor
Conflict of interest statement
Conflict of interest: P-R. Burgel reports grants from Vertex Pharmaceuticals and GSK, consulting fees from AstraZeneca, Chiesi, GSK, Insmed, Vertex, Viatris and Zambon, and travel support from AstraZeneca and Chiesi, outside the submitted work. P.J. Barry reports consulting fees from Insmed and Vertex, and lecture honoraria from Vertex and Chiesi, outside the submitted work.
Comment on
-
Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study.Eur Respir J. 2023 Dec 7;62(6):2202029. doi: 10.1183/13993003.02029-2022. Print 2023 Dec. Eur Respir J. 2023. PMID: 37945033 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous